At Ophthalmology Department of Civil Hospital of Culiacan, we investigated the inmediate effect of intravitreal injection of Bevacizumab on the IOP （intra ocular pressure） 30 min before and 24 h was measured after a...At Ophthalmology Department of Civil Hospital of Culiacan, we investigated the inmediate effect of intravitreal injection of Bevacizumab on the IOP （intra ocular pressure） 30 min before and 24 h was measured after application of 0.1 mL of Bevacizumab （Avastin） to 67 patients under sterile technique in operating room, with topical anesthetic tetracaine at 3.5 mm from the sclerocomeal junction. Pre-application average IOP was 13.5 ± 2.6 mmHg, and post-implementation IOP was 13.8 ± 2.6 mmHg. Diagnostics： PDR ＋ MESC （proliferative diabetic retinopathy with macular edema significant clinically） in 26 patients （38.8%）, NPDRSC （nonproliferative diabetic retinopathy significant clinical） in 14 patients （20.9%）, wet AMD （age related macular degeneration） in 14 patients （20.9%）, OCRV （occlusion central retinal vein） in 3 patients （4.5%）, OBRV （occlusion of branch retinal vein） in 3 patients （4.5%）, SCChR （serous central chorioretinopathy） in 2 patients （4.5%）, ChNnoA-R （choroidal neovasculaxization no age related） in 2 patients （3%）, CME （cystoid macular edema） in 2 patients （3%）.展开更多
文摘At Ophthalmology Department of Civil Hospital of Culiacan, we investigated the inmediate effect of intravitreal injection of Bevacizumab on the IOP （intra ocular pressure） 30 min before and 24 h was measured after application of 0.1 mL of Bevacizumab （Avastin） to 67 patients under sterile technique in operating room, with topical anesthetic tetracaine at 3.5 mm from the sclerocomeal junction. Pre-application average IOP was 13.5 ± 2.6 mmHg, and post-implementation IOP was 13.8 ± 2.6 mmHg. Diagnostics： PDR ＋ MESC （proliferative diabetic retinopathy with macular edema significant clinically） in 26 patients （38.8%）, NPDRSC （nonproliferative diabetic retinopathy significant clinical） in 14 patients （20.9%）, wet AMD （age related macular degeneration） in 14 patients （20.9%）, OCRV （occlusion central retinal vein） in 3 patients （4.5%）, OBRV （occlusion of branch retinal vein） in 3 patients （4.5%）, SCChR （serous central chorioretinopathy） in 2 patients （4.5%）, ChNnoA-R （choroidal neovasculaxization no age related） in 2 patients （3%）, CME （cystoid macular edema） in 2 patients （3%）.
